IRVINE, Calif., Jan. 5, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023.
Michael A. Mussallem, chairman and chief executive officer, is scheduled to present at 11:15 a.m. PT. Bernard Zovighian, president and incoming chief executive officer, and Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day.
Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on Facebook, Instagram, LinkedIn, Twitter and YouTube.
Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
Last Trade: | US$75.74 |
Daily Change: | -0.98 -1.28 |
Daily Volume: | 5,461,040 |
Market Cap: | US$44.470B |
July 24, 2025 May 01, 2025 April 23, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load